Stocks›Healthcare›RPRX

RPRX

Royalty Pharma plc

NasdaqResearch view

$58.21−0.14%

Sep 25 close · 1D EOD · Databento

HealthcarePharmaceutical PreparationsLarge-capSEC EDGAR FY 2025-12-31

What happened

Daily closes · dots are Wire stories

1 story has a settled receipt so far (1 on the Wire). The record starts speaking at three.

What’s next

Expected around early November, going by its own filing history. The company has not announced a date yet. Its matching report came Nov 5, 2025 and Nov 6, 2024, before the open.

Last report

Aug 5, 2026+0.47%

before the open

Last 4, next close

median 0.52% either way

up 4 of 4

Every report since 2023 →

DateEventSourceNext close

Sep 4Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsenGlobeNewswireGlobeNewswire−5.27%
Aug 5Earnings release, before the open · 8-KSEC EDGARSEC EDGAR ↗+0.47%

Next close = the first close after the event against the close before it. Prior-session closes only; not a call, not advice.

Big days · last year

Daily closes · Databento EOD

15 big days: a close more than 2.77% from the one before, three times RPRX’s median day (0.92%). On 10 of 15, its largest peers moved the same way at least half as far. We show what we hold, never a cause.

Shaded: since our stories began, Jun 10, 2026

15Sep 10, 2026
Sep 10, 2026Nothing in our recordNo RPRX story, brief or results filing in our record that dayGroup −0.2% did not move with it
−0.2% did not move with itMRK −1.9 · ABBV +1.6 · JNJ −0.3 · LLY −0.1
−3.04%
14Sep 8, 2026
Sep 8, 20261 storyRoyalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen · GlobeNewswireGroup −2.2% did not move with it
−2.2% did not move with itABBV −3.0 · JNJ −2.2 · LLY −2.2 · MRK −1.2
−5.27%
13Aug 19, 2026
Aug 19, 2026Nothing in our recordNo RPRX story, brief or results filing in our record that dayGroup +3.6% moved the same way
+3.6% moved the same wayMRK +12.6 · LLY +4.5 · ABBV +2.7 · JNJ +0.8
+3.42%
12Jul 16, 2026
Jul 16, 2026Nothing in our recordNo RPRX story, brief or results filing in our record that dayGroup +2.2% moved the same way
+2.2% moved the same wayABBV +4.2 · MRK +3.3 · JNJ +1.2 · LLY +1.1
+3.94%
11Jul 2, 2026
Jul 2, 2026Nothing in our recordNo RPRX story, brief or results filing in our record that dayGroup +3.5% moved the same way
+3.5% moved the same wayABBV +4.0 · JNJ +3.6 · MRK +3.3 · LLY +1.9
+3.57%
10Jun 26, 2026
Jun 26, 2026Nothing in our recordNo RPRX story, brief or results filing in our record that dayGroup +4.1% moved the same way
+4.1% moved the same wayLLY +7.1 · ABBV +4.2 · JNJ +4.0 · MRK +2.6
+2.82%
9Jun 23, 2026
Jun 23, 2026Nothing in our recordNo RPRX story, brief or results filing in our record that dayGroup +2.7% moved the same way
+2.7% moved the same wayMRK +3.6 · JNJ +3.4 · ABBV +2.1 · LLY +0.5
+3.32%
8May 13, 2026
May 13, 2026Before our storiesGroup +1.8% moved the same way
+1.8% moved the same wayJNJ +2.8 · LLY +2.6 · MRK +1.0 · ABBV +0.3
+3.00%
7Apr 17, 2026
Apr 17, 2026Before our storiesGroup +1.2% did not move with it
+1.2% did not move with itMRK +3.1 · LLY +2.5 · ABBV −0.3 · JNJ −0.1
+3.14%
6Mar 31, 2026
Mar 31, 2026Before our storiesGroup +1.9% moved the same way
+1.9% moved the same wayLLY +3.7 · ABBV +2.0 · MRK +1.9 · JNJ +0.8
+3.45%
5Mar 25, 2026
Mar 25, 2026Before our storiesGroup +1.7% moved the same way
+1.7% moved the same wayMRK +2.6 · JNJ +2.0 · LLY +1.5 · ABBV +1.0
+3.20%
4Mar 5, 2026
Mar 5, 2026Before our storiesGroup −2.2% moved the same way
−2.2% moved the same wayMRK −3.5 · JNJ −2.3 · LLY −2.0 · ABBV −1.6
−3.69%
3Nov 7, 2025
Nov 7, 2025Before our storiesGroup −0.1% did not move with it
−0.1% did not move with itLLY −1.4 · MRK +0.6 · JNJ −0.2 · ABBV +0.1
−5.44%
2Nov 5, 2025
Nov 5, 2025ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group +0.5% did not move with it
+0.5% did not move with itLLY +2.1 · MRK +0.6 · JNJ −0.5 · ABBV +0.4
+6.82%
1Oct 1, 2025
Oct 1, 2025Before our storiesGroup +6.5% moved the same way
+6.5% moved the same wayLLY +8.2 · MRK +7.4 · ABBV +5.5 · JNJ +0.3
+2.95%

A story on the same day is not a cause, and a group move is not proof either. Group: LLY, JNJ, ABBV, MRK, the largest companies in RPRX’s SEC industry; “the same way” means the same direction and at least half as far. Prior-session closes only; not a call, not advice.

The numbers · FY2025, filed

SEC EDGAR

Market cap$32.9B

Revenue$2.4B+5.10%

Net income$770.9M

EPS, diluted$1.78−6.80%

Operating margin65.6%

Return on equity7.9%

Debt / equity0.96

All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Market Cap$32.9B

Enterprise Value$41.6B

Income$770.9M

Sales$2.4B

Book/sh$25.03

Cash/sh$1.59

Dividend TTM—

Payout—

Employees—

IPO—

Quick Ratio—

Current Ratio2.40

Debt/Eq0.96

EPS (ttm)$1.78

EPS this Y-6.8%

EPS past 3/5Y161.1%

Sales past 3/5Y2.1%

EPS Y/Y TTM-6.8%

Sales Y/Y TTM5.1%

Shs Outstand388.13M

ROA3.9%

ROE7.9%

ROIC6.7%

Gross Margin—

Oper. Margin65.6%

Profit Margin32.4%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$2.3B

FY21

$2.2B

FY22

$2.4B

FY23

$2.3B

FY24

$2.4B

FY25

Operating leverage — margins

GrossOperatingNet

Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it

USD	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$2.3B	$2.2B	$2.4B	$2.3B	$2.4B
Gross Profit	—	—	—	—	—
Operating Income	$1.4B	$307.1M	$1.5B	$1.3B	$1.6B
Net Income	$619.7M	$42.8M	$1.1B	$859.0M	$770.9M
Diluted EPS	$1.49	$0.10	$2.53	$1.91	$1.78
Operating Cash Flow	$2.0B	$2.1B	$3.0B	$2.8B	$2.5B
Free Cash Flow	—	—	—	—	—

Same industry

In the screener →

LLY$1.11T JNJ$653.6B ABBV$467.1B MRK$367.1B ABT$175.3B PFE$163.4B VRTX$133.4B BMY$128.4B

Follow the news. Track the move.

RPRX story timeline

Company updates and connected market context, with the dated price move attached.

Stories

Direct

Sector context/Earnings

Sep 4

Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen

Novartis’ Phase 3 HORIZON trial for pelacarsen failed to reduce cardiovascular events in the overall study population, Royalty Pharma said Friday. The result removes a major potential royalty-growth catalyst for RPRX, although the filing’s full financial impact and any subgroup findings remain to be established.

Since story

-3.9%

2026-09-08 → 2026-09-25

GlobeNewswire · 23d ago

View both sides →

Follow the news. Track the move.